ACER THERAPEUTICS await FDA verdict June 25th

Investors eagerly await the FDA verdict on its NDA for Edviso, which is being evaluated for the treatment of vascular Ehlers -Danlos syndrome in patients with a confirmed type 111 collagen mutation. This for sure will be a market moving event.

AVERAGE ANALYSTS PRICE TARGET $51.40
AVERAGE RECOMMENDATION BUY

COMPANY PROFILE
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling in September 2017 and is headquartered in Newton, MA.